BioAllergenix Names Joshua Kayne as Executive Vice President, Sales and Marketing

Share Article

Joshua Kayne has joined BioAllergenix in the newly created position of Executive Vice President. BioAllergenix is an emerging leader in holistic and alternative health care focusing on the elimination of symptoms associated with chronic conditions such as allergies and migraines. Kayne will be directly responsible for global sales and marketing as the company expands its mindshare among both physicians and patients in the holistic care markets.

The goal is slow, steady and methodical growth by creating a foundation from which BioAllergenix can create a consistent experience for their customers and scalability through operations

BioAllergenix, an emerging industry leader in holistic and alternative health care, announced that Joshua Kayne has joined the company in the newly created position of Executive Vice President where he is directly responsible for the company's global sales and marketing. In this role, Kayne will lead the strategic planning for BioAllergenix's vision and growth as they look to expand their mindshare among both physicians and patients in the holistic care markets.

"The goal is slow, steady and methodical growth by creating a foundation from which BioAllergenix can create a consistent experience for their customers and scalability through operations" says Kayne. The plan includes the launch of a new name and brand slated for the late summer, rapid expansion of the sales force, the addition of a seminar series and integrated marketing touching targeted doctors online, offline and through a greatly enhanced public relations effort.

Mr. Kayne previously served in executive roles with national advertising firms based in Washington D.C., Atlanta and Palm Beach where he has had similar responsibilities for strategic growth and business development for clients in healthcare, finance, real estate, government, tourism, consumer goods and hospitality. He received a B.A. in Economics from Florida State University and maintains an active presence in numerous industry organizations.

"I am thrilled to be part of a company that has a truly revolutionary approach to healthcare and, more importantly, a committed patient before profit approach to the business. Our top priority is making doctors aware of our technology, taking a consultative approach in educating doctors that are interested and making it easy to acquire and integrate our devices into their practices," says Kayne. The math is simple: if more doctors have access to our technology, more patients get care. We've seen dramatic life changing results that our patients never thought would be possible and that's our end goal. I am looking forward to working on new methods of distribution for our products in safe, effective and responsible ways."

Adam Silbersweig, President of BioAllergenix, states, "We anticipate a rapidly increasing demand for holistic treatments, in general, and specifically for BioAllergenix therapies which are based upon neurological substance specific stress reduction. Joshua's expertise and direction will be crucial as the company enters its next stage of development."

For additional information, please contact BioAllergenix at 1-800-529-7640 or visit http://www.BAX3000webinar.com.

About BioAllergenix:
BioAllergenix was established in 2007 with the introduction of the BAX-3000. The BAX-3000 is the only FDA cleared device which is a fully-automated system that includes LASER (Light and Sound Energy Relaxation) Therapy. BioAllergenix's technology combines neurological substance specific stress reduction and environmental substance exposure to reduce or eliminate inappropriate anatomic nervous system mediated responses. These neurological responses are the triggers for symptoms associated with numerous chronic conditions such as allergies, asthma, migraines, chronic fatigue syndrome, irritable bowel syndrome, eczema and other skin conditions. BioAllergenix is committed to utilizing its technology to provide safe, fast, painless and noninvasive therapeutic alternatives rooted in neurological stress reduction therapy.

For more information, contact:
Beth Bay, Director of Public Relations
BioAllergenix
1-877-229-3000
http://www.BAX3000webinar.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Beth Bay
Visit website

Media